Payors Take Lead From FTC In Suing BI Over Its Orange Book Patent Listings For Inhalers

 
• By Brenda Sandburg

Class action complaint alleges Boehringer Ingelheim engaged in a ‘Respimat Orange Book scheme’ to thwart generic competition for Combivent Respimat and Spiriva Respimat that cost payors millions, if not billions, in overcharges.

Orange Book patent law
Lawsuit alleges Boehringer wrongly listed inhaler patents in FDA's Orange Book • Source: Shutterstock

More from Litigation

More from Legal & IP